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INTRODUCTION
The loudness dependence of auditory evoked potentials 
(LDAEP) is considered a valid indicator of central serotonergic 
activity in humans. The LDAEP has been identified as being in-
versely associated with central serotonergic activity,
1 with a weak 
LDAEP reflecting high serotonergic neurotransmission.
2 It was 
also found that blood serotonin concentration was negatively 
correlated with corresponding changes of the LDAEP in patients 
with major depression.
3 Serotonergic neurotransmission mod-
ulates sensory processing in the primary auditory cortex.
3,4 There-
fore the serotonergic system is well suited for a tonic modula-
tion of auditory cortical processing.
3 The reactivity of the auditory 
cortex can be assessed using LDAEP.
Based on these findings, there is a significant correlation be-
tween a strong LDAEP indicating low serotonergic function and 
a favorable response to SSRIs in depressed patients.
4,5 We hy-
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pothesized that LDAEP can be used to predict the individual pa-
tient’s tolerability and clinical response to SSRIs in major depres-
sion. We report herein a patient with major depressive disorder 
and a low baseline LDAEP, who showed low dose SSRI-induced 
adverse effects and that improved after the discontinuation of 
SSRIs and the administration of tianeptine. 
CASE 
A male with a 5-month history of major depressive disorder 
visited our hospital due to SSRI-induced adverse effects and a 
depressive episode (depressed mood, low interest, guilt, agita-
tion, and decreased concentration and appetite). He complained 
that he always experienced gastrointestinal trouble (e.g., nausea 
and vomiting), generalized weakness, headache, akathisia, and 
anxiety when taking SSRIs, and they disappeared completely 
after he discontinued the SSRIs. He had been treated at the psy-
chiatric outpatient clinic of another hospital for 3 weeks with 
fluoxetine and escitalopram in sequence. At his first visit to our 
hospital he had not taken his medication for 1 week, he had a 
Hamilton Rating Scale for Depression (HAMD) score of 21, a 
Beck Depression Inventory score of 21, and scored negative in 
the Mood Disorder Questionnaire. Before the antidepressant 
treatment, Event -related potential (ERP) using auditory stimu-
lation was measured. Auditory stimulation comprised 1,000 
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Hz stimuli with an interstimulus interval that was randomized 
between 500 and 900 ms. Tones of 1,000 Hz and 80-ms dura-
tion (10-ms rise and 10-ms fall) were presented at five inten-
sities (55, 65, 75, 85, and 95 dB SPL) via headphones. EEG data 
were recorded from 64 scalp sites using silver/silver-chloride elec-
trodes according to the international 10-20 system (impedance 
<10 kΩ) and using an Auditory Neuroscan SynAmp amplifier 
(Compumedics USA, El Paso, TX, USA). For each intensity and 
for the subject, the N1 peak and P2 peak were then determined 
at the Fz, Cz, and Pz electrodes. The peak-to-peak N1/P2 am-
plitudes were calculated for the five stimulus intensities, and the 
LDAEP was calculated as the linear-regression slope.
His LDAEP was found to be low, at -0.14, which indicates that 
his central serotonergic neurotransmission was already highly 
active. We therefore chose to prescribe an antidepressant unre-
lated to serotonin- reuptake inhibition. He was initially treated 
with tianeptine (12.5 mg) and clonazepam (0.5 mg) once daily. 
With no emergence of previously experienced AEs due to SS-
RIs, his depressive symptoms had improved substantially by day 
21, on which his HAMD score had decreased to 11. After 4weeks 
of this medication, the patient did not complain of any depres-
sive symptoms, and his HAMD score was 6.
DISCUSSION
We present a case with severe adverse effects after SSRI thera-
py. His LDAEP value was very low without medication, reflect-
ing high serotonergic functioning at baseline. We assumed that 
this patient had a low tolerance to SSRIs and did not respond 
well to them due to an overincrease of serotonergic activity which 
was already high. This was suggested by adverse effects appear-
ing whenever he took an SSRI. In contrast, no adverse effects oc-
curred when he took the antidepressant tianeptine, which does 
not cause serotonin-reuptake inhibition. 
LDAEP has been proposed as a biological marker of central 
serotonergic activity in major depression, with relevance to the 
clinical response to SSRIs.
4-7 Juckel et al.(2007) reported that 
responders to the citalopram treatment (serotonergic drug) 
were characterized by a strong LDAEP at baseline, and respond-
ers to reboxetine (nonserotonergic drug) were characterized by 
a weak LDAEP at baseline.
8
We have also reported that a strong LDAEP is related to a 
favorable response to acute SSRI treatment in generalized anxi-
ety disorder (GAD).
9 GAD patients with a favorable response to 
escitalopram treatment are characterized by a stronger pretreat-
ment LDAEP. Some investigators have reported a reduced LDAEP 
after an acute increase in serotonin levels following the admin-
istration of citalopram.
10 Hence, it can be assumed that major 
depressive disorder patients with a low tolerability will be char-
acterized by a weaker pretreatment LDAEP. 
Tianeptine, an “atypical” antidepressant whose pharmaco-
logical action differs from that of the “typical” reuptake-blocking 
agents, prevents stress-induced dendritic atrophy, improves neu-
rogenesis, reduces apoptosis, and normalizes metabolite levels 
and the hippocampal volume.
11 In addition, it decreases the ac-
tivity of serotonin and its levels in the serotonergic synapses of the 
central nervous system by increasing serotonin reuptake.
12 Thus, 
when SSRI causes adverse effects or when there is a low LDAEP 
value in patient with major depression, tianeptine or some other 
non-serotonin-related antidepressant should be prescribed. 
We described herein a major depressive disorder patient with 
a favorable response and tolerability to tianeptine, who was found 
to have a weak pretreatment LDAEP. Measurement of the 
LDAEP appears to provide useful clinical information for pre-
dicting the tolerability and treatment response to SSRIs in pa-
tients with major depressive disorder. However, the limitations 
of this single case report must be acknowledged. Especially, it 
is possible that the patient was a poor metabolizer to SSRI. 
Thus, further investigations with larger samples are needed.
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